Table 3 Sample demographics of study population, healthy and diabetic, and medication profile of diabetic volunteers
(a) Sample demographics of 20-Plex cytokine analysis, thromboelastography and lipogram analysis, healthy (n = 23) and diabetic (n = 25) volunteers | |||
|---|---|---|---|
|  | Healthy individuals (n = 23) | Diabetic individuals (n = 25) | P-values |
Gender | Male (n = 14) | Male (n = 13) |  |
Female (n = 9) | Female (n = 12) |  | |
Age (years) | 55.30 ± 3.59 | 59.75 ± 3.07 |  |
HbA1c (%) | 5.43 ± 0.10 | 9.05 ± 0.58 | < 0.0001 |
Diabetic medication | |||
 Hyperglycaemia medication | – | n = 17 (68.00%) |  |
 Hypertension medication | – | n = 16 (64.00%) |  |
 Hyperlipidaemia medication | – | n = 9 (36.00%) |  |
 Anticoagulant medication | – | n = 12 (48.00%) |  |
(b) Sample demographics of V-Plex vascular injury analysis, healthy (n = 36) and diabetic (n = 38) volunteers | |||
|---|---|---|---|
|  | Healthy individuals (n = 36) | Diabetic individuals (n = 38) | P-values |
Gender | Male (n = 16) | Male (n = 19) |  |
Female (n = 20) | Female (n = 19) |  | |
Age (years) | 58.11 ± 10.98 | 64.58 ± 12.42 |  |
HbA1c (%) | 5.25 ± 0.09 | 8.96 ± 0.46 | < 0.0001 |
Diabetic medication | |||
 Hyperglycaemia medication | – | n = 30 (83.33%) |  |
 Hypertension medication | – | n = 25 (69.44%) |  |
 Hyperlipidaemia medication | – | n = 18 (50.00%) |  |
 Anticoagulant medication | – | n = 19 (52.78%) |  |